To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

NCT05555212 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: QLH11811

Sponsor

Qilu Pharmaceutical Co., Ltd.